{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:53Z","timestamp":1791972773558,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:00:00Z","timestamp":1474588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1245\/s10434-016-5591-7","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T14:50:37Z","timestamp":1474642237000},"page":"450-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience"],"prefix":"10.1245","volume":"24","author":[{"given":"Mashaal","family":"Dhir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wallis","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel E.","family":"Tublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil B.","family":"Amesur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Orons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"issue":"1","key":"5591_CR1","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8\u2013e21.","journal-title":"Lancet Oncol."},{"issue":"18","key":"5591_CR2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol."},{"key":"5591_CR3","doi-asserted-by":"crossref","unstructured":"Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1\u201318, vii.","DOI":"10.1016\/j.ecl.2010.12.005"},{"issue":"1","key":"5591_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.soc.2015.08.010","volume":"25","author":"HA Farley","year":"2016","unstructured":"Farley HA, Pommier RF. Treatment of neuroendocrine liver metastases. Surg Oncol Clin N Am. 2016;25(1):217\u201325.","journal-title":"Surg Oncol Clin N Am."},{"issue":"13","key":"5591_CR5","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1245\/s10434-012-2462-8","volume":"19","author":"S Gaujoux","year":"2012","unstructured":"Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"5591_CR6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology."},{"issue":"6","key":"5591_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u201313.","journal-title":"N Engl J Med."},{"issue":"10022","key":"5591_CR8","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (Lond Engl). 2016;387(10022):968\u201377.","journal-title":"Lancet (Lond Engl)."},{"issue":"6","key":"5591_CR9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med."},{"key":"5591_CR10","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Wolin EM, Chasen B, et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. ASCO Meeting Abstracts. February 18, 2016 2016;34(4_suppl):194.","DOI":"10.1200\/jco.2016.34.4_suppl.194"},{"issue":"4","key":"5591_CR11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1245\/s10434-012-2786-4","volume":"20","author":"D Arrese","year":"2013","unstructured":"Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol. 2013;20(4):1114\u201320.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"5591_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminoncol.2010.03.004","volume":"37","author":"J Nazario","year":"2010","unstructured":"Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Sem Oncol. 2010;37(2):118\u201326.","journal-title":"Sem Oncol."},{"issue":"8","key":"5591_CR13","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590\u2013602.","journal-title":"Cancer."},{"issue":"2","key":"5591_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","volume":"36","author":"N Bhagat","year":"2013","unstructured":"Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Interv Radiol. 2013;36(2):449\u201359.","journal-title":"Cardiovasc Interv Radiol."},{"issue":"3","key":"5591_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11605-007-0089-z","volume":"11","author":"M Bloomston","year":"2007","unstructured":"Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11(3):264\u201371.","journal-title":"J Gastrointest Surg."},{"issue":"1","key":"5591_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","volume":"47","author":"F Fiore","year":"2014","unstructured":"Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177\u201382.","journal-title":"Endocrine."},{"issue":"3","key":"5591_CR17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00270-011-0122-1","volume":"34","author":"SK Gaur","year":"2011","unstructured":"Gaur SK, Friese JL, Sadow CA, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Interv Radiol. 2011;34(3):566\u201372.","journal-title":"Cardiovasc Interv Radiol."},{"issue":"3","key":"5591_CR18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012;56(3):609\u201317.","journal-title":"J Hepatol."},{"key":"5591_CR19","doi-asserted-by":"crossref","unstructured":"Hur S, Chung JW, Kim HC, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol JVIR. 2013;24(7):947\u201356; quiz 957.","DOI":"10.1016\/j.jvir.2013.02.030"},{"issue":"13","key":"5591_CR20","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","volume":"18","author":"SC Mayo","year":"2011","unstructured":"Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657\u201365.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"5591_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","volume":"12","author":"M Pericleous","year":"2016","unstructured":"Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia-Pacific J Clin Oncol. 2016;12(1):61\u20139.","journal-title":"Asia-Pacific J Clin Oncol."},{"issue":"11","key":"5591_CR22","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","volume":"12","author":"SC Pitt","year":"2008","unstructured":"Pitt SC, Knuth J, Keily JM, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastroint Surg. 2008;12(11):1951\u201360.","journal-title":"J Gastroint Surg."},{"issue":"7","key":"5591_CR23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","volume":"18","author":"AT Ruutiainen","year":"2007","unstructured":"Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol JVIR. 2007;18(7):847\u201355.","journal-title":"J Vasc Interv Radiol JVIR."},{"issue":"10","key":"5591_CR24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","volume":"51","author":"LM Dilz","year":"2015","unstructured":"Dilz LM, Denecke T, Steffen IG, et al. Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer (Oxf Engl 1990). 2015;51(10):1253\u201362.","journal-title":"Eur J Cancer (Oxf Engl 1990)"},{"issue":"22","key":"5591_CR25","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","volume":"23","author":"W Sun","year":"2005","unstructured":"Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897\u2013904.","journal-title":"J Clin Oncol."},{"key":"5591_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000403785","volume":"44","author":"J Strosberg","year":"2015","unstructured":"Strosberg J, Goldman J, Costa F, Pavel M. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Front Horm Res. 2015;44:239\u201347.","journal-title":"Front Horm Res."},{"issue":"3\u20134","key":"5591_CR27","first-page":"345","volume":"103","author":"P ClewemarAntonodimitrakis","year":"2015","unstructured":"ClewemarAntonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-FU for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology. 2015;103(3\u20134):345\u201353.","journal-title":"Neuroendocrinology."},{"issue":"1","key":"5591_CR28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hoc.2015.09.002","volume":"30","author":"CK Mulvey","year":"2016","unstructured":"Mulvey CK, Bergsland EK. Systemic therapies for advanced gastrointestinal carcinoid tumors. Hematol Oncol Clin N Am. 2016;30(1):63\u201382.","journal-title":"Hematol Oncol Clin N Am."},{"issue":"2","key":"5591_CR29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157\u201376.","journal-title":"Neuroendocrinology."},{"issue":"16","key":"5591_CR30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","volume":"33","author":"PL Kunz","year":"2015","unstructured":"Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855\u201363.","journal-title":"J Clin Oncol."},{"issue":"3","key":"5591_CR31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med."},{"issue":"12","key":"5591_CR32","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","volume":"96","author":"JC Yao","year":"2011","unstructured":"Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"15","key":"5591_CR33","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","volume":"25","author":"D Campana","year":"2007","unstructured":"Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967\u201373.","journal-title":"J Clin Oncol."},{"issue":"2","key":"5591_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-12-0340","volume":"20","author":"M Ter-Minassian","year":"2013","unstructured":"Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Cancer. 2013;20(2):187\u201396.","journal-title":"Endocr Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5591-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T23:30:50Z","timestamp":1568417450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5591-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["5591"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5591-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,23]]}}}